Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 10/2005

01-10-2005 | Original Paper

The tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone stimulates proliferation of immortalized human pancreatic duct epithelia through β-adrenergic transactivation of EGF receptors

Authors: Minoo D. F. Askari, Ming-Sound Tsao, Hildegard M. Schuller

Published in: Journal of Cancer Research and Clinical Oncology | Issue 10/2005

Login to get access

Abstract

Purpose: Pancreatic ductal adenocarcinoma is an aggressive smoking-associated human cancer in both men and women. The nicotine-derived 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) is thought to contribute to the development of these neoplasms in smokers through genotoxic effects. However, NNK has been recently identified as an agonist for both β1- and β2-adrenergic receptors. Binding of NNK to these receptors stimulates proliferation of pulmonary and pancreatic adenocarcinomas cells in vitro and in hamster models. The goal of this study was to elucidate the NNK effects on the signal transduction pathways downstream of both β1- and β2-adrenergic receptors in immortalized human pancreatic HPDE6-c7 cells. Methods: The HPDE6-c7 cells are developed from normal pancreatic duct epithelial cells which are the putative cells of origin of pancreatic ductal adenocarcinoma. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide (MTT) cell proliferation assays, Western blot and cyclic AMP assays were employed to demonstrate the effects of NNK and other β1- and β2-adrenergic agonists and antagonist treatments on these cells. Results: MTT cell proliferation assays demonstrated that NNK and the classic β-adrenergic agonist, isoproterenol, increased cell proliferation in HPDE6-c7 cells. Western blot and cyclic AMP assays demonstrated that NNK treatments also resulted in: (1) transactivation of the epidermal growth factor receptor, EGFR, (2) an increase in intracellular cyclic AMP accumulation, and (3) phosphorylation of mitogen-activated protein kinase, Erk1/2. The proliferative response to NNK and isoproterenol were inhibited by the use of beta-blockers (propranolol), and the inhibitors of adenylyl cyclase (SQ 22536), EGFR-specific tyrosine kinase (AG 1478) and Erk (PD 98059). Conclusion: These findings suggest that the NNK -mediated β-adrenergic receptor transactivation of the EGFR and phosphorylation of Erk1/2 in immortalized human pancreatic duct epithelial cells as a novel mechanism might contribute to the development of tobacco-associated pancreatic carcinogenesis.
Literature
1.
go back to reference Miller BA, Silverman DT, Kaplan R (1993) Pancreas. Cancer Statistics Review: 1973–1990. In: Miller BA, Ries LA, Hanky BF et al (eds) Bethesda, NIH Publication #93–2789, NCI Miller BA, Silverman DT, Kaplan R (1993) Pancreas. Cancer Statistics Review: 1973–1990. In: Miller BA, Ries LA, Hanky BF et al (eds) Bethesda, NIH Publication #93–2789, NCI
2.
go back to reference Gold EB, Cameron JL (1993) Chronic pancreatitis and the risk of pancreatic cancer. N Engl J Med 323:1485–1486CrossRef Gold EB, Cameron JL (1993) Chronic pancreatitis and the risk of pancreatic cancer. N Engl J Med 323:1485–1486CrossRef
3.
go back to reference Lowenfels AB, Maisonneuve P, Cavalline G et al (1993) The International Pancreatic Study Group. Pancreatitis and risk of pancreatic cancer. N Engl J Med 328:1433–1437CrossRefPubMed Lowenfels AB, Maisonneuve P, Cavalline G et al (1993) The International Pancreatic Study Group. Pancreatitis and risk of pancreatic cancer. N Engl J Med 328:1433–1437CrossRefPubMed
4.
go back to reference Hecht SS (1996) Recent studies on the mechanisms of bioactivation and detoxification of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), a tobacco-specific lung carcinogen. CRC Cri Rev Toxicol 26:163–181CrossRef Hecht SS (1996) Recent studies on the mechanisms of bioactivation and detoxification of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), a tobacco-specific lung carcinogen. CRC Cri Rev Toxicol 26:163–181CrossRef
5.
go back to reference Belinsky A, Devereux TR, Maronpot RR, Stoner GD, Anderson MW (1989) The relationship between the formation of promutagenic adducts and the activation of the K-ras protooncogene in lung tumors from A/J mice treated with nitrosamines. Cancer Res 40:5305–5311 Belinsky A, Devereux TR, Maronpot RR, Stoner GD, Anderson MW (1989) The relationship between the formation of promutagenic adducts and the activation of the K-ras protooncogene in lung tumors from A/J mice treated with nitrosamines. Cancer Res 40:5305–5311
6.
go back to reference Sakorafas GH, Tsiotou AG, Tsitos GG (2000) Molecular biology of pancreatic cancer; oncogenes, tumor suppressor genes, growth factors, and their receptors from a clinical perspective. Cancer Treat Rev 26:29–52CrossRefPubMed Sakorafas GH, Tsiotou AG, Tsitos GG (2000) Molecular biology of pancreatic cancer; oncogenes, tumor suppressor genes, growth factors, and their receptors from a clinical perspective. Cancer Treat Rev 26:29–52CrossRefPubMed
7.
go back to reference Schuller HM, Zhang L, Weddle DL, Castonguay A, Walker K, Miller MS (2002) The cyclooxygenase inhibitor ibuprofen and the FLAP inhibitor MK886 inhibit pancreatic carcinogenesis induced in hamsters by transplacental exposure to ethanol and the tobacco carcinogen NNK. J Cancer Res Clin Oncol 128:525–532CrossRefPubMed Schuller HM, Zhang L, Weddle DL, Castonguay A, Walker K, Miller MS (2002) The cyclooxygenase inhibitor ibuprofen and the FLAP inhibitor MK886 inhibit pancreatic carcinogenesis induced in hamsters by transplacental exposure to ethanol and the tobacco carcinogen NNK. J Cancer Res Clin Oncol 128:525–532CrossRefPubMed
8.
go back to reference Ikematsu Y, Liu G, Fienhold MA et al (1997) In vitro pancreatic ductal cell carcinogenesis. Int J Cancer 72:1095–1103CrossRefPubMed Ikematsu Y, Liu G, Fienhold MA et al (1997) In vitro pancreatic ductal cell carcinogenesis. Int J Cancer 72:1095–1103CrossRefPubMed
9.
go back to reference Schuller HM, Tithof PK, Williams M, Plummer III HK (1999) The tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone is a ß-adrenergic agonist and stimulates DNA synthesis in lung adenocarcinoma via ß-adrenergic receptor-mediated release of arachidonic acid. Cancer Res 59:4510–4515PubMed Schuller HM, Tithof PK, Williams M, Plummer III HK (1999) The tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone is a ß-adrenergic agonist and stimulates DNA synthesis in lung adenocarcinoma via ß-adrenergic receptor-mediated release of arachidonic acid. Cancer Res 59:4510–4515PubMed
10.
go back to reference Weddle DL, Tithoff P, Williams M, Schuller HM (2001) Beta-adrenergic growth regulation of human cancer cell lines derived from pancreatic ductal carcinomas. Carcinogenesis 22:473–479CrossRefPubMed Weddle DL, Tithoff P, Williams M, Schuller HM (2001) Beta-adrenergic growth regulation of human cancer cell lines derived from pancreatic ductal carcinomas. Carcinogenesis 22:473–479CrossRefPubMed
11.
go back to reference Novak I (1998) Beta-adrenergic regulation of ion transport in pancreatic ducts: patch-clamp study of isolated rat pancreatic ducts. Gastroenterology 115:714–721CrossRefPubMed Novak I (1998) Beta-adrenergic regulation of ion transport in pancreatic ducts: patch-clamp study of isolated rat pancreatic ducts. Gastroenterology 115:714–721CrossRefPubMed
12.
go back to reference Alvarez C, Regan JP, Bass BL (2002) Influence of epidermal growth factor on bovine pancreatic duct cell bicarbonate. J Surg Res 106:54–61CrossRefPubMed Alvarez C, Regan JP, Bass BL (2002) Influence of epidermal growth factor on bovine pancreatic duct cell bicarbonate. J Surg Res 106:54–61CrossRefPubMed
13.
go back to reference Tobita K, Kijima H, Dowaki S et al (2003) Epidermal growth factor receptor expression in human pancreatic cancer: significance for liver metastasis. Int J Mol med 11:305–309PubMed Tobita K, Kijima H, Dowaki S et al (2003) Epidermal growth factor receptor expression in human pancreatic cancer: significance for liver metastasis. Int J Mol med 11:305–309PubMed
14.
go back to reference Clarke LE, Leitzel K, Smith J, Ali SM, Lipton A (2003) Epidermal growth factor receptor mRNA in peripheral blood of patients with pancreatic, lung and colon carcinomas detected by RT-PCR. Int J Oncol 22:425–430PubMed Clarke LE, Leitzel K, Smith J, Ali SM, Lipton A (2003) Epidermal growth factor receptor mRNA in peripheral blood of patients with pancreatic, lung and colon carcinomas detected by RT-PCR. Int J Oncol 22:425–430PubMed
15.
go back to reference Ouyang H, Mou Lj, Luk C, Liu N, Karaskova J, Squire J, Tsao MS (2000) Immortal human pancreatic duct epithelial cell lines with near normal genotype and phenotype. Am J Pathol 157:1623–1631PubMed Ouyang H, Mou Lj, Luk C, Liu N, Karaskova J, Squire J, Tsao MS (2000) Immortal human pancreatic duct epithelial cell lines with near normal genotype and phenotype. Am J Pathol 157:1623–1631PubMed
16.
go back to reference Daaka Y, Luttrell LM, Lefkowitz RJ (1997) Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A. Nature 390:88–91CrossRefPubMed Daaka Y, Luttrell LM, Lefkowitz RJ (1997) Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A. Nature 390:88–91CrossRefPubMed
17.
go back to reference Maudsley S, Pierce KL, Zamah AM et al (2000) The beta(2)-adrenergic receptor mediates extracellular signal-regulated kinase activation via assembly of a multi-receptor complex with the epidermal growth factor receptor. J Biol Chem 275:9572–9580CrossRefPubMed Maudsley S, Pierce KL, Zamah AM et al (2000) The beta(2)-adrenergic receptor mediates extracellular signal-regulated kinase activation via assembly of a multi-receptor complex with the epidermal growth factor receptor. J Biol Chem 275:9572–9580CrossRefPubMed
18.
go back to reference Luttrell LM (2002) Activation and targeting of mitogen-activated protein kinases by G-protein-coupled receptors. Can J Physiol Pharmacol 80:375–382CrossRefPubMed Luttrell LM (2002) Activation and targeting of mitogen-activated protein kinases by G-protein-coupled receptors. Can J Physiol Pharmacol 80:375–382CrossRefPubMed
19.
go back to reference Borda ES, Tenenbaum A, Sales ME, Rumi L, and Sterin-Borda L (1998) Role of arachidonic acid metabolites in the action of a ß adrenergic agonist on human monocytes. Prostaglandins leukotrienes essent. Fatty Acids 58:85–90CrossRef Borda ES, Tenenbaum A, Sales ME, Rumi L, and Sterin-Borda L (1998) Role of arachidonic acid metabolites in the action of a ß adrenergic agonist on human monocytes. Prostaglandins leukotrienes essent. Fatty Acids 58:85–90CrossRef
20.
go back to reference Schlosser W, Schlosser S, Ramadani M, Gansauge F, Gansauge S, Beger HG (2002) Cyclooxygenase-2 is overexpressed in chronic pancreatitis. Pancreas 25(1):26–30CrossRefPubMed Schlosser W, Schlosser S, Ramadani M, Gansauge F, Gansauge S, Beger HG (2002) Cyclooxygenase-2 is overexpressed in chronic pancreatitis. Pancreas 25(1):26–30CrossRefPubMed
21.
go back to reference Schuller HM, Porter B, Riechert A (2000) Beta-adrenergic modulation of NNK-induced lung carcinogenesis in hamsters. J Cancer Res Clin Oncol 126:624–630PubMedCrossRef Schuller HM, Porter B, Riechert A (2000) Beta-adrenergic modulation of NNK-induced lung carcinogenesis in hamsters. J Cancer Res Clin Oncol 126:624–630PubMedCrossRef
22.
go back to reference Schuller HM (2002) Mechanisms of smoking-related lung and pancreatic adenocarcinoma development. Nat Rev Cancer 2:455–463CrossRefPubMed Schuller HM (2002) Mechanisms of smoking-related lung and pancreatic adenocarcinoma development. Nat Rev Cancer 2:455–463CrossRefPubMed
23.
go back to reference Treisman R (1996) Regulation of transcription by MAP kinase cascades. Curr Opin Cell Biol 8:205–215CrossRefPubMed Treisman R (1996) Regulation of transcription by MAP kinase cascades. Curr Opin Cell Biol 8:205–215CrossRefPubMed
24.
go back to reference Garrington TP, Johnson GL (1999) Organization and regulation of mitogen-activated protein kinase signaling pathways. Curr Opin Cell Biol 11:211–221CrossRefPubMed Garrington TP, Johnson GL (1999) Organization and regulation of mitogen-activated protein kinase signaling pathways. Curr Opin Cell Biol 11:211–221CrossRefPubMed
25.
go back to reference Daub H, Weiss FU, Wallasch C, Ullrich A (1996) Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature 379:557–560CrossRefPubMed Daub H, Weiss FU, Wallasch C, Ullrich A (1996) Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature 379:557–560CrossRefPubMed
26.
go back to reference Daub H, Wallasch C, Lankenau A, Herrlich A, Ullrich A (1997) Signal characteristics of G protein-transactivated EGF receptor. EMBO J 1:7032–7044CrossRef Daub H, Wallasch C, Lankenau A, Herrlich A, Ullrich A (1997) Signal characteristics of G protein-transactivated EGF receptor. EMBO J 1:7032–7044CrossRef
27.
go back to reference Luttrell LM, Della Rocca GJ, van Biesen T, Luttrell DK, Lefkowitz RJ (1997) J Biol Chem 272:4637–4644CrossRefPubMed Luttrell LM, Della Rocca GJ, van Biesen T, Luttrell DK, Lefkowitz RJ (1997) J Biol Chem 272:4637–4644CrossRefPubMed
28.
go back to reference Korc M (1998) Role of growth factors in pancreatic cancer. Surg Oncol Clin N Am 7:25–41PubMed Korc M (1998) Role of growth factors in pancreatic cancer. Surg Oncol Clin N Am 7:25–41PubMed
29.
go back to reference Korc M, Chandrasekar B, Yamanaka Y, Friess H, Büchler MW, Beger HG (1992) Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Investig 90:1352–1360PubMedCrossRef Korc M, Chandrasekar B, Yamanaka Y, Friess H, Büchler MW, Beger HG (1992) Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Investig 90:1352–1360PubMedCrossRef
30.
go back to reference Zhu Z, Kleeff J, Friess H, Wang L et al (2000) Epiregulin is up-regulated in pancreatic cancer and stimulates pancreatic cancer cell growth. Biochem Biophys Res Commun 273:1019–1024CrossRefPubMed Zhu Z, Kleeff J, Friess H, Wang L et al (2000) Epiregulin is up-regulated in pancreatic cancer and stimulates pancreatic cancer cell growth. Biochem Biophys Res Commun 273:1019–1024CrossRefPubMed
31.
go back to reference Piiper A, Dikic I, Lutz MP, d Zeuzem S (2002) Cyclic AMP induces transactivation of the receptors for epidermal growth factor and nerve growth factor, thereby modulating activation of MAP kinase, Akt, and neurite outgrowth in PC12 cells. J Biol Chem 277:43623–43630CrossRefPubMed Piiper A, Dikic I, Lutz MP, d Zeuzem S (2002) Cyclic AMP induces transactivation of the receptors for epidermal growth factor and nerve growth factor, thereby modulating activation of MAP kinase, Akt, and neurite outgrowth in PC12 cells. J Biol Chem 277:43623–43630CrossRefPubMed
32.
go back to reference Park PG, Merryman J, Orloff M, Schuller HM (1995) Beta-adrenergic mitogenic signal transduction in peripheral lung adenocarcinoma: implications for individuals with preexisting chronic lung disease. Cancer Res 55:3504–3508PubMed Park PG, Merryman J, Orloff M, Schuller HM (1995) Beta-adrenergic mitogenic signal transduction in peripheral lung adenocarcinoma: implications for individuals with preexisting chronic lung disease. Cancer Res 55:3504–3508PubMed
Metadata
Title
The tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone stimulates proliferation of immortalized human pancreatic duct epithelia through β-adrenergic transactivation of EGF receptors
Authors
Minoo D. F. Askari
Ming-Sound Tsao
Hildegard M. Schuller
Publication date
01-10-2005
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 10/2005
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-005-0002-7

Other articles of this Issue 10/2005

Journal of Cancer Research and Clinical Oncology 10/2005 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.